New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Stock Information for CareView Communications Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CareView Communications Inc

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Artelo Biosciences Announces Reverse Stock Split
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.